Double-blind, randomized, placebo-controlled, Phase II/III trial on the efficacy and tolerability of treatment with budesonide oral suspension vs. placebo in children and adolescents with eosinophilic esophagitis
- Conditions
- eosinophilic eosphagitiseosinophylic gullet inflammation10017969
- Registration Number
- NL-OMON50028
- Lead Sponsor
- Dr. Falk Pharma GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 9
Inclusion criteria for DB-treatment phase:
- Signed informed consent
- Male or female patients, >=2 to <18 years of age
- Confirmed clinico-pathological diagnosis of EoE according to established
diagnostic criteria
- Clinically and histologically active EoE
- Negative pregnancy test in female patients of childbearing potential
Exclusion criteria for DB treatment phase:
- Erosive gastroesophageal reflux disease (GERD)
- Achalasia, scleroderma esophagus, or systemic sclerosis
- Other clinically evident causes than EoE for esophageal eosinophilia
- Any concomitant esophageal disease and relevant gastro-intestinal disease
(celiac disease, inflammatory bowel disease, oropharyngeal or esophageal
bacterial, viral, or untreated or inadequately treated fungal infection
[candida esophagitis])
- Any known relevant infectious diseases (e.g., AIDS defining disease, active
tuberculosis, hepatitis B, or hepatitis C)
- Diabetes mellitus
- If careful medical monitoring is not ensured: cardiovascular disease,
hypertension, osteoporosis, active peptic ulcer disease, glaucoma, cataract, or
infection
- History of cancer in the last five years
- History of esophageal surgery at any time or of esophageal dilation
procedures within the last 4 weeks prior to screening endoscopy, or need for an
immediate endoscopic intervention due to a stricture
- Upper gastrointestinal bleeding within 8 weeks prior to screening endoscopy
- Existing or intended pregnancy or breast-feeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method